Princeton, United States
Slayback Pharma, founded in 2011, is a specialty pharmaceutical company based in the United States. They focus on developing and manufacturing complex generic pharmaceutical products, placing significant emphasis on complex injectables and non-solid oral products. Their portfolio stands out through strategic product selection and execution, supported by a network of contract R&D laboratories and manufacturing organizations.
By leveraging sophisticated manufacturing and innovative drug delivery technologies, Slayback Pharma has successfully established a unique presence in the Biopharma, Manufacturing, and Pharmaceutical industries. Their distinctive approach is summarized by their slogan: "Slayback Pharma believes every pharmaceutical product exhibits its own unique personality."
The company's growth trajectory witnessed a significant boost with a $50.00M Series B investment from Everstone Capital on 06 January 2020. This funding underscores investor confidence in Slayback Pharma's innovative capabilities and market potential.
Lyrus